Filter
21
Filtered Results: 21
Text search:
B.
Dongmo-Nguimfack
Featured
Recommendations
2
New Publications
3
Language
Document type
No document type
12
Studies & Reports
4
Guidelines
4
Manuals
1
Countries / Regions
Global
1
Africa
1
Authors & Publishers
Publication Years
Category
HIV & STI
5
Virology
2
Communicable Diseases
1
Hepatitis
1
Under-5 nutrition
1
Primary Health Care
1
Toolboxes
Clinical Aspects, Treatment & Prevention
7
Antiretroviral Treatment ART
7
Access to treatment and laboratory
5
Treatment Guidelines HIV
4
General Reports
2
HIV testing & services
2
TB/HIV Coinfection
2
Treatment & Prevention
1
Clinical Aspects
1
Opportunistic Infections
1
Prevention Guidelines
1
Universal Health Coverage UHC and 90-90-90 Strategy
1
Supply Chain & Store Management
1
Postexposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP)
1
Neurological Disorders
1
TB/HIV Global
1
HIV service delivery
1
Reports & Studies
1
Neurological disorders, Others
1
Eastern Europe and central Asia
1
WHO/HIV/SIP
Accessed: 28.11.2019
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...
The 2030 health-related Sustainable Development Goals call on countries to end AIDS as a public health threat and also to achieve universal health coverage. The World Health Organization (WHO) promotes primary health care (PHC) as the key mechanism for achieving universal health coverage, and the PH...
July 2018
This fourth edition of the Unitaid/WHO market and technology landscape: HIV rapid diagnostic tests for self-testing report summarizes the current HIV testing gap; the challenges facing efforts to scale up; and the potential role HIV self-testing (HIVST) could play to achieve the United...
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep...
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach.
These guidelines bring in...
Supplement to the 2016 consolidated Guidelines on the use of antiretroviral drugs for Treating and Preventing HIV infection
HIV Treatment
Recomendaciones para un enfoque de salud pública
Segunda edición 2016
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0169530 February 16, 2017
Consolidated guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection
recommended
2nd edition. These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention,...
Technical Report
AIDS Medicines and diagnostics service
September 2016
Jamieson D and Kellerman S. Journal of the International AIDS Society 2016, 19:20917 http://www.jiasociety.org/index.php/jias/article/view/20917 | http://dx.doi.org/10.7448/IAS.19.1.20917
Technical Report
AIDS Medicines and diagnostics service
July 2015
The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ...
Second Edition
AIDS Medicines and diagnostics services
July 2015
Recommandations pour une Approche de Santé publique.
Juin 2013.
Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines.
This summary assesses the current state of evidence on each approach in tabular form, providing: the definition and objectives; evidence of effectiveness; operational considerations (e.g., training, staffing, and logistics); cost considerations and evidence on cost-effectiveness; operational success...
